What is the 7MM historical and forecasted market for Autosomal Dominant Polycystic Kidney Disease?

 

What is the Autosomal Dominant Polycystic Kidney Disease Market?

DelveInsight’s ‘Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as Autosomal Dominant Polycystic Kidney Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Know which Autosomal Dominant Polycystic Kidney Disease is expected to score the touchdown first- Autosomal Dominant Polycystic Kidney Disease Market

What is the Autosomal Dominant Polycystic Kidney Disease Market Report?

The Autosomal Dominant Polycystic Kidney Disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted 7MM Autosomal Dominant Polycystic Kidney Disease market size from 2019–2032. The report also covers current Autosomal Dominant Polycystic Kidney Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Get an Exclusive Copy of the Report Here- Autosomal Dominant Polycystic Kidney Disease Market Forecast

What is Autosomal Dominant Polycystic Kidney Disease Overview?

Autosomal dominant polycystic kidney disease, also called “adult PKD” is the most common inherited kidney disorder characterized by the growth of cysts in the kidneys, which eventually leads to kidney failure. A monogenetic disorder, Autosomal Dominant Polycystic Kidney Disease is caused by mutations in either the PKD1 gene found on chromosome 16 or the PKD2 gene found on chromosome 4. Mutations in PKD1 are more common and account for about 85% of all Autosomal Dominant Polycystic Kidney Disease cases.

What is the Autosomal Dominant Polycystic Kidney Disease Diagnosis and Treatment?

Ultrasound is the most reliable, inexpensive, and non-invasive way to diagnose PKD. If someone at risk for PKD is older than 40 years and has a normal ultrasound of the kidneys, they probably do not have PKD. Occasionally, a CT scan (computed tomography scan) and MRI (magnetic resonance imaging) may detect smaller cysts that ultrasound cannot find. MRI is mostly used to measure and monitor the volume and growth of kidneys and cysts. In some situations, genetic testing might also be done. This involves a blood test that checks for abnormal genes that cause the disease. Genetic testing is not recommended for everyone. The test is costly, and it also fails to detect PKD in about 15% of people who have it.

In the case of treatment, there is no proper cure for Autosomal Dominant Polycystic Kidney Disease. However, treatment of hypertension in patients with Autosomal Dominant Polycystic Kidney Disease commonly includes nonpharmacological interventions, such as exercise, weight reduction, and dietary salt restriction. Excluding additional secondary causes of hypertension, such as primary hyperaldosteronism, pheochromocytoma, or obstructive sleep apnea, should all be considered with clinical suspicion of their existence. Also, inhibition of the RAAS using angiotensin-converting enzyme (ACE) inhibitors is favored, as well as the use of angiotensin-receptor blockers (ARBs) and β-blockers. The findings from the early studies with small cohorts of patients demonstrated that ACE inhibitors reduce the severity of proteinuria and left ventricular mass compared to diuretics and calcium channel blockers. In contrast, ARBs resulted in a greater reduction in proteinuria than calcium channel blockers.

Autosomal Dominant Polycystic Kidney Disease Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent cases of Autosomal Dominant Polycystic Kidney Disease, Age-specific cases of Autosomal Dominant Polycystic Kidney Disease, and Mutation-specific cases of Autosomal Dominant Polycystic Kidney Disease, the scenario of Autosomal Dominant Polycystic Kidney Disease in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032. 

Autosomal Dominant Polycystic Kidney Disease Key Findings

·         Total diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in the 7MM were found to be approximately 367,042 cases in the year 2021. The diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease are likely to change by 2032 in the forecast period 2022─2032.

·         The United States accounted for approximately 142,709 diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in the year 2021.

·         In 2021, the total reported diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in EU-5 countries were approximately 193,161 cases which are expected to rise by 2032.

·         In 2021, the UK accounted for the highest number of Autosomal Dominant Polycystic Kidney Disease diagnosed prevalent cases (67,419), followed by France (61,282) among EU-5 countries. In contrast, Italy accounts for the lowest number of cases of Autosomal Dominant Polycystic Kidney Disease diagnosed prevalent population in EU-5.

·         As per DelveInsight analysis, in Japan, Autosomal Dominant Polycystic Kidney Disease cases in the age groups <5, 5–14, 15–24, 25–44, 45–64, and ≥65 years were observed to be approximately 62, 62, 125, 3,429, 19,576, and 7,918, respectively in 2021. The age-specific cases are expected to change by 2032.

For further information on Market Impact by therapies, download Autosomal Dominant Polycystic Kidney Disease Market Sample @ Autosomal Dominant Polycystic Kidney Disease Market Size

Key Questions Answered in the Autosomal Dominant Polycystic Kidney Disease Market Report

·         What was the Autosomal Dominant Polycystic Kidney Disease market share (%) distribution in 2019 and how it would look like in 2032?

·         What would be the Autosomal Dominant Polycystic Kidney Disease total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?

·         What are the key findings of the market across the 7MM and which country will have the largest Autosomal Dominant Polycystic Kidney Disease market size during the forecast period (2022–2032)?

·         At what CAGR, the Autosomal Dominant Polycystic Kidney Disease market is expected to grow at the 7MM level during the forecast period (2022–2032)?

·         What would be the Autosomal Dominant Polycystic Kidney Disease market outlook across the 7MM during the forecast period (2022–2032)?

·         What would be the Autosomal Dominant Polycystic Kidney Disease market growth till 2032 and what will be the resultant market size in the year 2032?

·         How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

What are the Autosomal Dominant Polycystic Kidney Disease Market Companies?

Some of the key players of Autosomal Dominant Polycystic Kidney Disease market includes Otsuka Pharmaceutical Co. Ltd, AceLink Therapeutics Inc., Novotech Pty Limited, Palladio Biosciences, Novartis Pharmaceuticals, and many others.

Discover more about therapy set to grab substantial Autosomal Dominant Polycystic Kidney Disease Market Landscape @ Autosomal Dominant Polycystic Kidney Disease Market Share

Table of Content

1. Key Insights

2. Report Introduction

3. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance

4. Autosomal Dominant Polycystic Kidney Disease Market: Future Perspective

5. Executive Summary of Autosomal Dominant Polycystic Kidney Disease

6. Key Events

7. Disease Background and Overview

8. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population

9. Patient Journey

10. Autosomal Dominant Polycystic Kidney Disease Marketed Drugs

11. Autosomal Dominant Polycystic Kidney Disease Emerging Drugs

12. Autosomal Dominant Polycystic Kidney Disease: Seven Major Market Analysis

13. Region-Wise Market size of Autosomal Dominant Polycystic Kidney Disease

14. Key Opinion Leaders’ Views

15. Autosomal Dominant Polycystic Kidney Disease Market Drivers

16. Autosomal Dominant Polycystic Kidney Disease Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Reimbursement and Market Access

20 Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Get to know more information about the market share of Autosomal Dominant Polycystic Kidney Disease treatment therapies @ Autosomal Dominant Polycystic Kidney Disease Market Companies

Recently Launched Market Research Reports 2022 by DelveInsight

·         Cataract Surgery Complications Market Trend

·         Oncolytic Virus Cancer Therapy Pipeline

·         Medical Marijuana Market

·         AL Amyloidosis Market

·         Ranibizumab Biosimilars Insight

·         Systemic Mastocytosis Market

·         Trichomoniasis Market

·         Temporomandibular Disorders Market 

·         Alpha Thalassemia Market 

·         Membranous Nephropathy Market

·         Orthopedic Power Devices Market

·         Urethral Stricture Treatment Devices Market

·         Lice Infestations Market

·         Ocular Hypertension Market

·         Wolman Disease Market

·         Acute Myeloid Leukemia Market

·         Open-Angle Glaucoma Market

·         Tay-Sachs Disease Market

·         Vulvovaginal Candidiasis Market

·         Gastritis Market

·         Japan Healthcare Outlook Market          

·         Behcet’s Disease Market

·         Lambert-Eaton Myasthenic Syndrome Market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.